Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Medical Oncology
Erschienen in: Medical Oncology 2/2013

01.06.2013 | Review Article

Breast cancer screening: review of benefits and harms, and recommendations for developing and low-income countries

verfasst von: Meteb Al-Foheidi, Mubarak M. Al-Mansour, Ezzeldin M. Ibrahim

Erschienen in: Medical Oncology | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Breast cancer is the most common cancer in women worldwide. The disease remains a public health concern as recent evidence indicates that the breast cancer burden has increased mainly in developing and low-income countries (DLICs). Despite the demonstrated benefits, the debate about the real benefits and harms of breast cancer screening is ongoing. Many experts believe that the benefits of screening, in terms of reduced breast cancer mortality, outweigh the harms, whereas others think the opposite. In this review, we assess the clinical utility of available screening modalities, present evidence, overdiagnosis, cost-effectiveness, and other pertinent issues. We also examine relevant data from DLICs to underscore the barriers and challenges that impede implementation of screening strategies in those populations. We also provide recommendations concerning rational preventive strategies for breast cancer control for women in DLICs.
Literatur
1.
Forouzanfar MH, Foreman KJ, Delossantos AM, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet. 2011;378:1461–84.PubMedCrossRef
2.
Parkin DM, Ferlay J, Curado MP, et al. Fifty years of cancer incidence: Ci5 i–ix. Int J Cancer. 2010;127:2918–27.PubMedCrossRef
3.
Porter P. “Westernizing” women’s risks? Breast cancer in lower-income countries. N Engl J Med. 2008;358:213–6.PubMedCrossRef
4.
Gakwaya A, Kigula-Mugambe JB, Kavuma A, et al. Cancer of the breast: 5-year survival in a tertiary hospital in Uganda. Br J Cancer. 2008;99:63–7.PubMedCrossRef
5.
6.
Ibrahim EM, Zeeneldin AA, Sadiq BB, et al. The present and the future of breast cancer burden in the kingdom of Saudi Arabia. Med Oncol. 2008;25:387–93.PubMedCrossRef
7.
Babay ZA, Addar MH, Shahid K, et al. Age at menarche and the reproductive performance of Saudi women. Ann Saudi Med. 2004;24:354–6.PubMed
8.
Khalid ME. The prevalence of abdominal obesity and its associated risk factors in married, non-pregnant women born and living in high altitude, southwestern, Saudi Arabia. Saudi Med J. 2007;28:1875–80.PubMed
9.
Al-Hazzaa HM. Prevalence of physical inactivity in saudi arabia: a brief review. East Mediterr Health J. 2004;10:663–70.
10.
Farahat FM, Joshi KP, Al-Mazrou FF. Assessment of nutritional status and lifestyle pattern among Saudi Arabian school children. Saudi Med J. 2007;28:1298–300.PubMed
11.
Ibrahim EM, al-Mulhim FA, al-Amri A, et al. Breast cancer in the eastern province of Saudi Arabia. Med Oncol. 1998;15:241–7.PubMedCrossRef
12.
Ezzat AA, Ibrahim EM, Raja MA, et al. Locally advanced breast cancer in Saudi Arabia: high frequency of stage iii in a young population. Med Oncol. 1999;16:95–103.PubMedCrossRef
13.
El Saghir NS, Khalil MK, Eid T, et al. Trends in epidemiology and management of breast cancer in developing Arab countries: a literature and registry analysis. Int J Surg. 2007;5:225–33.PubMedCrossRef
14.
Abulkhair OA, Al Tahan FM, Young SE, et al. The first national public breast cancer screening program in Saudi Arabia. Ann Saudi Med. 2010;30:350–7.PubMed
15.
Dandash KF, Al-Mohaimeed A. Knowledge, attitudes, and practices surrounding breast cancer and screening in female teachers of Buraidah, Saudi Arabia. Int J Health Sci. 2007;1:61–71.
16.
Semiglazov VF, Sagaidak VN, Moiseyenko VM, et al. Study of the role of breast self-examination in the reduction of mortality from breast cancer. The Russian federation/world health organization study. Eur J Cancer. 1993;29A:2039–46.PubMed
17.
Thomas DB, Gao DL, Ray RM, et al. Randomized trial of breast self-examination in shanghai: final results. J Natl Cancer Instit. 2002;94:1445–57.CrossRef
18.
Kosters JP, Gotzsche PC. Regular self-examination or clinical examination for early detection of breast cancer. Cochrane Database Syst Rev. 2003;(2):CD003373.
19.
IARC, Working group on the evaluation of cancer-prevention strategies. In: Breast cancer screening, vol. 7. Lyon, France: IARC Press; 2002. p. 87–117.
20.
Barton MB, Harris R, Fletcher SW. The rational clinical examination. Does this patient have breast cancer? The screening clinical breast examination: should it be done? How? JAMA. 1999;282:1270–80.PubMedCrossRef
21.
Shapiro S. Evidence on screening for breast cancer from a randomized trial. Cancer. 1977;39:2772–82.PubMedCrossRef
22.
Shapiro S. Periodic screening for breast cancer: the hip randomized controlled trial. Health insurance plan. J Natl Cancer Inst Monogr. 1997;(22):27–30.
23.
Pisani P, Parkin DM, Ngelangel C, et al. Outcome of screening by clinical examination of the breast in a trial in the Philippines. Int J Cancer. 2006;118:149–54.PubMedCrossRef
24.
Boulos S, Gadallah M, Neguib S, et al. Breast screening in the emerging world: high prevalence of breast cancer in Cairo. Breast. 2005;14:340–6.PubMedCrossRef
25.
26.
Miller AB, To T, Baines CJ, et al. Canadian national breast screening study-2: 13-year results of a randomized trial in women aged 50–59 years. J Natl Cancer Instit. 2000;92:1490–9.CrossRef
27.
Denewer A, Hussein O, Farouk O, et al. Cost-effectiveness of clinical breast assessment-based screening in rural Egypt. World J Surg. 2010;34:2204–10.PubMedCrossRef
28.
Ravert PK, Huffaker C. Breast cancer screening in women: an integrative literature review. J Am Acad Nurse Pract. 2010;22:668–73.PubMedCrossRef
29.
Mandelson MT, Oestreicher N, Porter PL, et al. Breast density as a predictor of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Instit. 2000;92:1081–7.CrossRef
30.
Zahl PH, Strand BH, Maehlen J. Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study. BMJ. 2004;328:921–4.PubMedCrossRef
31.
Elmore JG, Barton MB, Moceri VM, et al. Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med. 1998;338:1089–96.PubMedCrossRef
32.
Elmore JG, Armstrong K, Lehman CD, et al. Screening for breast cancer. JAMA. 2005;293:1245–56.PubMedCrossRef
33.
Castells X, Roman M, Romero A, et al. Breast cancer detection risk in screening mammography after a false-positive result. Cancer Epidemiol. 2013;37(1):85–90.
34.
Weinstein SP, Localio AR, Conant EF, et al. Multimodality screening of high-risk women: a prospective cohort study. J Clin Oncol. 2009;27:6124–8.PubMedCrossRef
35.
Pisano ED, Gatsonis C, Hendrick E, et al. Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med. 2005;353:1773–83.PubMedCrossRef
36.
Carney PA, Miglioretti DL, Yankaskas BC, et al. Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med. 2003;138:168–75.PubMedCrossRef
37.
Skaane P. Studies comparing screen-film mammography and full-field digital mammography in breast cancer screening: updated review. Acta Radiol. 2009;50:3–14.PubMedCrossRef
38.
Tosteson AN, Stout NK, Fryback DG, et al. Cost-effectiveness of digital mammography breast cancer screening. Ann Intern Med. 2008;148:1–10.PubMedCrossRef
39.
Crystal P, Strano SD, Shcharynski S, et al. Using sonography to screen women with mammographically dense breasts. AJR. 2003;181:177–82.PubMedCrossRef
40.
Berg WA, Blume JD, Cormack JB, et al. Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer. JAMA. 2008;299:2151–63.PubMedCrossRef
41.
Corsetti V, Houssami N, Ferrari A, et al. Breast screening with ultrasound in women with mammography-negative dense breasts: evidence on incremental cancer detection and false positives, and associated cost. Eur J Cancer. 2008;44:539–44.PubMedCrossRef
42.
Corsetti V, Houssami N, Ghirardi M, et al. Evidence of the effect of adjunct ultrasound screening in women with mammography-negative dense breasts: interval breast cancers at 1 year follow-up. Eur J Cancer. 2011;47:1021–6.PubMedCrossRef
43.
Smith RA, Cokkinides V, Brooks D, et al. Cancer screening in the United States, 2011: a review of current American cancer society guidelines and issues in cancer screening. CA Cancer J Clin. 2011;61:8–30.PubMedCrossRef
44.
45.
Anderson BO, Braun S, Lim S, et al. Early detection of breast cancer in countries with limited resources. Breast J. 2003;9(Suppl 2):S51–9.PubMedCrossRef
46.
Lenner P, Jonsson H. Excess mortality from breast cancer in relation to mammography screening in northern Sweden. J Med Screen. 1997;4:6–9.PubMed
47.
Alexander FE. The edinburgh randomized trial of breast cancer screening. J Natl Cancer Inst Monogr. 1997;(22):31–5.
48.
Anonymous. 16-year mortality from breast cancer in the UK trial of early detection of breast cancer. Lancet. 1999;353:1909–14.
49.
Tabar L, Vitak B, Chen HH, et al. Update of the Swedish two-county trial of breast cancer screening: histologic grade-specific and age-specific results. Swiss surgery = Schweizer Chirurgie = Chirurgie suisse = Chirurgia svizzera. 1999;5:199–204.PubMedCrossRef
50.
51.
Narod SA. On being the right size: a reappraisal of mammography trials in Canada and Sweden. Lancet. 1997;349:1846.PubMedCrossRef
52.
Gotzsche PC, Olsen O. Is screening for breast cancer with mammography justifiable? Lancet. 2000;355:129–34.PubMedCrossRef
53.
54.
Anonymous. Independent UK panel on breast cancer screening. The benefits and harms of breast cancer screening: an independent review. Lancet. 2012;380(9855):1778-86.
55.
Harris R, Yeatts J, Kinsinger L. Breast cancer screening for women ages 50 to 69 years a systematic review of observational evidence. Prev Med. 2011;53:108–14.PubMedCrossRef
56.
Coldman A, Phillips N, Warren L, et al. Breast cancer mortality after screening mammography in British Columbia women. Int J Cancer. 2007;120:1076–80.PubMedCrossRef
57.
Feig SA. Effect of service screening mammography on population mortality from breast carcinoma. Cancer. 2002;95:451–7.PubMedCrossRef
58.
Zahl PH, Gotzsche PC, Andersen JM, et al. Results of the two-county trial of mammography screening are not compatible with contemporaneous official Swedish breast cancer statistics. Dan Med Bull. 2006;53:438–40.PubMed
59.
Kalager M, Zelen M, Langmark F, et al. Effect of screening mammography on breast-cancer mortality in Norway. N Engl J Med. 2010;363:1203–10.PubMedCrossRef
60.
Anonymous. Summaries for patients. Screening for breast cancer: recommendations from the U.S. Preventive services task force. Ann Intern Med. 2002;137:I47.
61.
Humphrey LL, Helfand M, Chan BK, et al. Breast cancer screening: a summary of the evidence for the U.S. Preventive services task force. Ann Intern Med. 2002;137:347–60.PubMedCrossRef
62.
Nelson HD, Tyne K, Naik A, et al. Screening for breast cancer: an update for the U.S. Preventive services task force. Ann Intern Med. 2009;151:727–37, W237–42.
63.
Mandelblatt JS, Cronin KA, Bailey S, et al. Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med. 2009;151:738–47.PubMedCrossRef
64.
Wai ES, D’Yachkova Y, Olivotto IA, et al. Comparison of 1- and 2-year screening intervals for women undergoing screening mammography. Br J Cancer. 2005;92:961–6.PubMedCrossRef
65.
Goel A, Littenberg B, Burack RC. The association between the pre-diagnosis mammography screening interval and advanced breast cancer. Breast Cancer Res Treat. 2007;102:339–45.PubMedCrossRef
66.
White E, Miglioretti DL, Yankaskas BC, et al. Biennial versus annual mammography and the risk of late-stage breast cancer. J Natl Cancer Instit. 2004;96:1832–9.CrossRef
67.
Miller AB, To T, Baines CJ, et al. The Canadian national breast screening study-1: breast cancer mortality after 11 to 16 years of follow-up. A randomized screening trial of mammography in women age 40 to 49 years. Ann Intern Med. 2002;137:305–12.PubMedCrossRef
68.
Hellquist BN, Duffy SW, Abdsaleh S, et al. Effectiveness of population-based service screening with mammography for women ages 40 to 49 years: evaluation of the swedish mammography screening in young women (scry) cohort. Cancer. 2011;117:714–22.PubMedCrossRef
69.
Weedon-Fekjaer H. Effectiveness of population-based service screening with mammography for women ages 40 to 49 years: evaluation of the swedish mammography screening in young women (scry) cohort. Cancer. 2012;118:1169; author reply 70–1.
70.
Jorgensen KJ, Gyotzsche PC. Unclear methods in estimate of screening effect in women ages 40 to 49 years. Cancer. 2012;118:1170; author reply 70–1.
71.
Mandelblatt JS, Schechter CB, Yabroff KR, et al. Toward optimal screening strategies for older women. Costs, benefits, and harms of breast cancer screening by age, biology, and health status. J Gen Intern Med. 2005;20:487–96.PubMedCrossRef
72.
Lash TL, Fox MP, Buist DS, et al. Mammography surveillance and mortality in older breast cancer survivors. J Clin Oncol. 2007;25:3001–6.PubMedCrossRef
73.
Badgwell BD, Giordano SH, Duan ZZ, et al. Mammography before diagnosis among women age 80 years and older with breast cancer. J Clin Oncol. 2008;26:2482–8.PubMedCrossRef
74.
Mandelblatt J, Saha S, Teutsch S, et al. The cost-effectiveness of screening mammography beyond age 65 years: a systematic review for the U.S. Preventive services task force. Ann Intern Med. 2003;139:835–42.PubMedCrossRef
75.
76.
Yu J, Park A, Morris E, et al. MRI screening in a clinic population with a family history of breast cancer. Ann Surg Oncol. 2008;15:452–61.PubMedCrossRef
77.
Liberman L. Breast cancer screening with MRI—what are the data for patients at high risk? N Engl J Med. 2004;351:497–500.PubMedCrossRef
78.
Lehman CD, Smith RA. The role of MRI in breast cancer screening. JNCCN. 2009;7:1109–15.PubMed
79.
Grann VR, Patel PR, Jacobson JS, et al. Comparative effectiveness of screening and prevention strategies among brca1/2-affected mutation carriers. Breast Cancer Res Treat. 2011;125:837–47.PubMedCrossRef
80.
Boyd NF, Guo H, Martin LJ, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med. 2007;356:227–36.PubMedCrossRef
81.
Wright H, Listinsky J, Rim A, et al. Magnetic resonance imaging as a diagnostic tool for breast cancer in premenopausal women. Am J Surg. 2005;190:572–5.PubMedCrossRef
82.
83.
Autier P, Boniol M, Middleton R, et al. Advanced breast cancer incidence following population-based mammographic screening. Ann Oncol. 2011;22:1726–35.PubMedCrossRef
84.
Autier P, Boniol M. The incidence of advanced breast cancer in the west midlands, United Kingdom. Eur J Cancer Prev. 2012;21:217–21.PubMedCrossRef
85.
Shen Y, Yang Y, Inoue LY, et al. Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Instit. 2005;97:1195–203.CrossRef
86.
Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med. 2012;367:1998–2005.PubMedCrossRef
87.
Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353:1784–92.PubMedCrossRef
88.
89.
Fallowfield LJ, Hall A. Psychosocial and sexual impact of diagnosis and treatment of breast cancer. Br Med Bull. 1991;47:388–99.PubMed
90.
Berry DA, Baines CJ, Baum M, et al. Flawed inferences about screening mammography’s benefit based on observational data. J Clin Oncol. 2009;27:639–40; author reply 41–2.
91.
Moss SM, Cuckle H, Evans A, et al. Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years’ follow-up: a randomised controlled trial. Lancet. 2006;368:2053–60.PubMedCrossRef
92.
Harford JB. Breast-cancer early detection in low-income and middle-income countries: do what you can versus one size fits all. Lancet Oncol. 2011;12:306–12.PubMedCrossRef
93.
Ontario Health Services. Cancer screening with digital mammography for women at average risk for breast cancer, magnetic resonance imaging (MRI) for women at high risk: an evidence-based analysis. Ont Health Technol Assess Ser. 2010;10:1–55.
94.
Berrington de Gonzalez A, Berg CD, Visvanathan K, et al. Estimated risk of radiation-induced breast cancer from mammographic screening for young BRCA mutation carriers. J Natl Cancer Instit. 2009;101:205–9.CrossRef
95.
Sigurdsson K, Sigvaldason H. Effectiveness of cervical cancer screening in Iceland, 1964–2002: a study on trends in incidence and mortality and the effect of risk factors. Acta Obstet Gynecol Scand. 2006;85:343–9.PubMedCrossRef
96.
Jensen AR, Madsen AH, Overgaard J. Trends in breast cancer during three decades in Denmark: stage at diagnosis, surgical management and survival. Acta Oncol. 2008;47:537–44.PubMedCrossRef
97.
Kalager M, Adami HO, Bretthauer M, et al. Overdiagnosis of invasive breast cancer due to mammography screening: results from the Norwegian screening program. Ann Intern Med. 2012;156:491–9.PubMedCrossRef
98.
Groot MT, Baltussen R, Uyl-de Groot CA, et al. Costs and health effects of breast cancer interventions in epidemiologically different regions of Africa, North America, and Asia. Breast J. 2006;12(Suppl 1):S81–90.PubMedCrossRef
99.
Okonkwo QL, Draisma G, der Kinderen A, et al. Breast cancer screening policies in developing countries: a cost-effectiveness analysis for India. J Natl Cancer Instit. 2008;100:1290–300.CrossRef
100.
Wong IO, Kuntz KM, Cowling BJ, et al. Cost-effectiveness analysis of mammography screening in Hong Kong Chinese using state-transition markov modelling. Hong Kong Med J. 2010;16(Suppl 3):38–41.PubMed
101.
Szeto KL, Devlin NJ. The cost-effectiveness of mammography screening: evidence from a microsimulation model for New Zealand. Health Policy. 1996;38:101–15.PubMedCrossRef
102.
Somdatta P, Baridalyne N. Awareness of breast cancer in women of an urban resettlement colony. Indian J Cancer. 2008;45:149–53.PubMedCrossRef
103.
Yip CH, Smith RA, Anderson BO, et al. Guideline implementation for breast healthcare in low- and middle-income countries: early detection resource allocation. Cancer. 2008;113:2244–56.PubMedCrossRef
104.
Rasu RS, Rianon NJ, Shahidullah SM, et al. Effect of educational level on knowledge and use of breast cancer screening practices in Bangladeshi women. Health Care Women Int. 2011;32:177–89.PubMedCrossRef
105.
Ibrahim NA, Odusanya OO. Knowledge of risk factors, beliefs and practices of female healthcare professionals towards breast cancer in a tertiary institution in Lagos, Nigeria. BMC cancer. 2009;9:76.PubMedCrossRef
106.
Garg P, Bansal M, Garg M, et al. Creating awareness about the painless nature of early breast cancer lump is important in low-income countries. Breast J. 2010;16:101–2.PubMedCrossRef
107.
Hajian S, Vakilian K, Najabadi KM, et al. Effects of education based on the health belief model on screening behavior in high risk women for breast cancer, Tehran, Iran. APJCP. 2011;12:49–54.PubMed
108.
Caleffi M, Ribeiro RA, Bedin AJ Jr, et al. Adherence to a breast cancer screening program and its predictors in underserved women in southern brazil. Cancer Epidemiol Biomarkers Prevent. 2010;19:2673–9.CrossRef
109.
Azaiza F, Cohen M, Awad M, et al. Factors associated with low screening for breast cancer in the Palestinian authority: relations of availability, environmental barriers, and cancer-related fatalism. Cancer. 2010;116:4646–55.PubMedCrossRef
110.
Dunn RA, Tan A, Samad I. Does performance of breast self-exams increase the probability of using mammography: evidence from Malaysia. APJCP. 2010;11:417–21.PubMed
111.
Barrett B, McKenna P. Communicating benefits and risks of screening for prostate, colon, and breast cancer. Fam Med. 2011;43:248–53.PubMed
112.
Gotzsche PC, Hartling OJ, Nielsen M, et al. Breast screening: the facts–or maybe not. BMJ. 2009;338:b86.PubMedCrossRef
113.
Bello M. Awareness is the first step in battle against breast cancer. Bull World Health Organ. 2012;90:164–5.PubMedCrossRef
114.
Anderson GL, Neuhouser ML. Obesity and the risk for premenopausal and postmenopausal breast cancer. Cancer Prevent Res (Philadelphia, Pa). 2012;5:515–21.CrossRef
115.
Griggs JJ, Mangu PB, Anderson H, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2012;30:1553–61.PubMedCrossRef
116.
Schmid SM, Eichholzer M, Bovey F, et al. Impact of body mass index on compliance and persistence to adjuvant breast cancer therapy. Breast. 2012;21:487–92.PubMedCrossRef
117.
Lee IM, Shiroma EJ, Lobelo F, et al. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. Lancet. 2012;380:219–29.PubMedCrossRef
118.
Ibrahim EM, Al-Homaidh A. Physical activity and survival after breast cancer diagnosis: meta-analysis of published studies. Med Oncol. 2011;28:753–65.PubMedCrossRef
119.
Anderson BO, Yip CH, Smith RA, et al. Guideline implementation for breast healthcare in low-income and middle-income countries: overview of the Breast Health Global Initiative global summit 2007. Cancer. 2008;113:2221–43.PubMedCrossRef
120.
Sharma K, Costas A, Shulman LN, et al. A systematic review of barriers to breast cancer care in developing countries resulting in delayed patient presentation. J Oncol. 2012;2012:121873.PubMedCrossRef
Metadaten
Titel
Breast cancer screening: review of benefits and harms, and recommendations for developing and low-income countries
verfasst von
Meteb Al-Foheidi
Mubarak M. Al-Mansour
Ezzeldin M. Ibrahim
Publikationsdatum
01.06.2013
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 2/2013
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-013-0471-5

Weitere Artikel der Ausgabe 2/2013

Medical Oncology 2/2013 Zur Ausgabe

Original Paper

Expression and clinical significance of apolipoprotein E in pancreatic ductal adenocarcinoma

Short Communication

Solitary fibrous tumor of the pleura

Original Paper

Overexpression of TFIIB-related factor 2 is significantly correlated with tumor angiogenesis and poor survival in patients with esophageal squamous cell cancer

Original Paper

Expression of CD133 in acute leukemia

Original Paper

IRF4 promotes cell proliferation by JNK pathway in multiple myeloma

Original Paper

Association between single nucleotide polymorphisms of the transforming growth factor-beta1 gene and overall survival in unresectable locally advanced non-small-cell lung cancer patients treated with radio(chemo)therapy in a Chinese population

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise